Burkitt lymphoma responds to EPOCH-rituximab

被引：0
|
作者：
不详
机构：
来源：
EUROPEAN JOURNAL OF CANCER | 2007年 / 43卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：470 / 470
页数：1
相关论文
共 50 条
  • [21] DA-EPOCH-R for Adult Burkitt's Lymphoma: Pros and Cons
    Alderuccio, Juan Pablo
    Lossos, Izidore S.
    JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (11) : 676 - +
  • [22] Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia
    Thomas, Deborah A.
    Kantarjian, Hagop M.
    Faderl, Stefan
    Wierda, William G.
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Ferrajoli, Alessandra
    Verstovsek, Srdan
    Burger, Jan A.
    Fayad, Luis
    Romaguera, Jorge E.
    Garris, Rebecca
    Cortes, Jorge E.
    O'Brien, Susan
    BLOOD, 2011, 118 (21) : 1159 - 1160
  • [23] Caspase-independent killing of Burkitt lymphoma cell lines by rituximab
    I. Daniels
    A. M. Abulayha
    B. J. Thomson
    A. P. Haynes
    Apoptosis, 2006, 11 : 1013 - 1023
  • [24] Caspase-independent killing of Burkitt lymphoma cell lines by rituximab
    Daniels, I
    Abulayha, AM
    Thomson, BJ
    Haynes, AP
    APOPTOSIS, 2006, 11 (06) : 1013 - 1023
  • [25] Adult Burkitt Lymphoma: An Institutional Experience With Uniform DA-EPOCH-R Protocol
    Gogia, Ajay
    Kumar, Sudhir
    Sharma, Atul
    Gupta, Ritu
    Mallick, Soumyaranjan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S376 - S376
  • [26] DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?
    Hertzberg, Mark
    Joske, David J. L.
    Gandhi, Maher K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3722 - +
  • [27] Outcome with the hyper-CVAD and rituximab regimen in Burkitt (BL) and Burkitt-like (BLL) leukemia/lymphoma
    Thomas, DA
    Cortes, J
    Faderl, S
    O'Brien, S
    Beran, M
    Koller, C
    Garcia-Manero, G
    Younes, A
    Fayad, L
    Wierda, W
    Pierce, S
    Giles, FJ
    Kantarjian, H
    BLOOD, 2004, 104 (11) : 901A - 901A
  • [28] Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphoma by inducing apoptosis
    Xiaowen Ge
    Jianfeng Chen
    Ling Li
    Peipei Ding
    Qi Wang
    Wei Zhang
    Luying Li
    Xinyue Lv
    Danlei Zhou
    Zhengzeng Jiang
    Haiying Zeng
    Yifan Xu
    Yingyong Hou
    Weiguo Hu
    Cell Death & Disease, 10
  • [29] Dose-adjusted EPOCH-rituximab: A novel pharmacodynamic regimen with high efficacy in all clinical risk groups, and GCB and ABC subtypes of untreated diffuse large B-cell lymphoma
    Wilson, W
    Dunleavy, K
    Pittaluga, S
    Grant, N
    Steinberg, S
    Raffeld, M
    Jaffe, E
    Staudt, L
    Janik, J
    ANNALS OF ONCOLOGY, 2005, 16 : 69 - 69
  • [30] Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy
    Tan, Jing Yuan
    Qiu, Tian Yu
    Chiang, Jianbang
    Tan, Ya Hwee
    Yang, Valerie Shiwen
    Chang, Esther Wei Yin
    Poon, Eileen
    Somasundaram, Nagavalli
    Farid, Mohamad
    Tao, Miriam
    Lim, Soon Thye
    Chan, Jason Yongsheng
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 586 - 596
12345